ACCC logo
Facebook  LinkedIn  Twitter  ACCC Youtube Channel  ACCCBuzz blog

Association of Community Cancer Centers

The leading education and advocacy organization for the multidisciplinary cancer team

ACCCBuzz Blog  Find a Cancer Program  Log in to MyNetwork

Home > Resources > Virtual Tumor Boards in Molecular Testing > Overview

Molecular Testing in the Community Oncology Setting

Virtual Molecular Tumor Boards

As molecular testing becomes more widely adopted in the community oncology setting, cancer programs can benefit from access to innovative formats to help ensure that communication and quality patient care standards are maintained. Several innovative ACCC member programs have begun using virtual tumor board models as part of the integration of molecular testing into practice.

The virtual format allows participation by a variety of providers across a wide geographic area. Members of multidisciplinary teams across sites are invited to join in the virtual discussion of cases and determine treatment—regardless of the physical location of the patient and care team.

Building on interviews with select ACCC member programs, ACCC and our partner organization, the Association for Molecular Pathology (AMP), are developing a webinar series focused on virtual molecular tumor boards for lung and breast cancer. The 12-webinar series features case studies and robust discussions on molecular testing in the community setting.

Register now to add scheduled webinar dates to your calendar and view archived webinars. Once registered, you will receive automatic schedule alerts for the remainder of the series.

Virtual Molecular Tumor Boards: An Educational Series

ACCC has partnered with the Association for Molecular Pathology to host a series of 12 educational webinars featuring case-based lessons surrounding Molecular Testing for Breast and Lung Cancer. Register now to receive automatic updates on upcoming dates in this series. Presentations will feature experts from leading cancer programs:

Upcoming Webinars

The New Age of Molecular Testing and Targeted Therapies for Lung Cancer

Friday, April 28, 2017
3:15 – 4:15 PM EDT

Melissa L. Johnson, MD
Sarah Cannon Research Institute, Tennessee Oncology

Recent advances in lung cancer molecular testing and targeted therapies are leading to greater options for patients, including the approval of multiple agents for the treatment of advanced NSCLC patients with EGFR, ALK, or ROS1 mutations. This webinar will highlight ongoing advances and updates in lung cancer molecular testing and the potential clinical role of emerging agents on the horizon.

This webinar is presented in conjunction with the Tennessee Oncology Practice Society (TOPS).

Challenging Issues in Breast Cancer Management

Thursday, May 4, 2017
3:00 - 4:00 PM EDT

Michele Carpenter, MD
David Margileth, MD
St. Joseph Hospital of Orange, The Center for Cancer Prevention and Treatment

Ongoing research continues to reveal new advances in the clinical management of breast cancer. However, controversy still exists around certain issues as clinicians wait for more compelling evidence to change how they treat patients. Hear physicians review the current state and future direction of molecular testing policies and guidelines for breast cancer.

Engaging Multidisciplinary Clinicians in Genomic Tumor Boards

Tuesday, May 16, 2017
10:00 - 11:00 AM EDT

Presenter: Steven Powell, MD
Sanford Cancer Center

Developing a successful genomic tumor board requires effective engagement strategies to demonstrate value to providers with varying levels of understanding about cancer genomics. Education and outreach tactics must reach clinicians who work in different locations or specialize in treating specific malignancies. Hear how one ACCC-member cancer program’s journey in building a genomic tumor board led to increased engagement and communication across the clinical care team and provided new treatment options for patients with complex cancers.

Register Now
Archived Webinars

Clinical Genetics vs. Tumor Genomic Profiling: Relevance in Cancer Care

Olufunmilayo I. Olopade, MD, FACP
The University of Chicago Medicine

As the precision medicine landscape continues to evolve, the relevance of clinical genetics is intersecting with the advancing science of tumor genomic profiling. Gain a greater understanding of the clinical relevance of genetics vs. genomic profiling specific to breast cancer care, and the differences between hereditary/germline vs. somatic mutations.

Originally presented March 24, 2017.

Replay Coming Soon

The Role of Genetics Professionals in a Community Cancer Program

Megan Landsverk, PhD, FACMG
Patricia Crotwell, PhD, FACMG
Sanford Cancer Center

Community cancer programs can expand patient services by including experts in molecular genetics and tumor genomics on their multidisciplinary team. Learn how these professionals contribute to the development of personalized genomic testing, analysis of pharmacogenetic factors to predict cancer prognosis and response to treatment, and the cytogenetic analysis of cancer.

Originally presented on March 16, 2017.

View On-Demand Replay

An Ongoing Journey to Advance Molecular Testing in Lung Cancer

John Maurice, MD
Enza Esposito-Nguyen, RN, MSN, ANP-BC
Lavinia Dobrea, RN, MS, OCN
St. Joseph Hospital of Orange, The Center for Cancer Prevention and Treatment

St. Joseph Hospital of Orange has been on a continuous journey to advance their molecular testing processes in patients with lung cancer. Starting with a project based around the Lean methodology, the thoracic oncology team identified ways to improve tissue acquisition, testing processes, and clinical trial enrollment. Gain insight into their ongoing journey in process improvement and clinical care excellence.

Originally presented on March 13, 2017.

View On-Demand Replay

Virtual Tumor Boards: Precision Medicine and Personalized Cancer Therapy in Lung Cancer

Jeffrey Gregg, MD
Clinical Pathology Director, Molecular Diagnostics Professor of Pathology, Department of Pathology and Laboratory Medicine
University of California, Davis Medical Center

Lung cancer is one of the most common types of cancer, but every tumor is unique and may harbor rare, cancer-causing mutations. The application of precision medicine in lung cancer will be reviewed through two case studies, with a focus on how genomic profiling can guide targeted treatment decisions.

Originally presented on January 25, 2017.

View On-Demand Replay

Overview of Genomic Profiling

Jeffrey Gregg, MD
Senior Director, Clinical Pathology Director, Molecular Diagnostics Professor of Pathology, Department of Pathology and Laboratory Medicine
University of California, Davis Medical Center

Advances in molecular testing capabilities are leading clinicians to perform genomic profiling to identify potentially actionable targets for treatment. This webinar will provide a broad overview of some recent advances in genomic testing and explain how results may impact treatment decisions on a practical level.

Originally presented on December 14, 2016.

View On-Demand Replay

Virtual Molecular Tumor Board: Breast Cancer Case Studies

Arvind Chaudhry, MD, PhD, Summit Cancer Centers
V.K. Gadi, MD, PhD, Seattle Cancer Care Alliance

Joseph Kim, MD, Xaphesis

Listen to the discussion on case related topics including triple negative breast cancer, benefits and recommendations for molecular testing, HER2-directed therapies, and more.

This is webinar 2 of 12 in the Virtual Molecular Tumor Boards: An Educational Series, presented by ACCC and AMP. Please stay tuned for upcoming webinar topics and dates in this series.

Originally presented on October 26, 2016.

View On-Demand Replay

Using Virtual Molecular Tumor Boards to Access the Experts
LIVE from ACCC 33rd National Oncology Conference

Joseph Kim, MD, MPH, MBA, Xaphesis

Annie Chapman, MPH, Seattle Cancer Care Alliance
Eric Duncavage, MD, Washington University in St. Louis
Mark S. Soberman, MD, MBA, FACS, Frederick Regional Health System

In this first webinar of the virtual molecular tumor board series, hear from a multidisciplinary panel on how cancer programs can form valuable relationships with research centers for access to experts to translate the latest developments in molecular testing to appropriate individual patient treatment recommendations. Compare various tumor board models, partnership benefits, and effective practices.

Originally presented on October 20, 2016.

View On-Demand Replay

Copyright © 2017 Association of Community Cancer Centers. All Rights Reserved.
1801 Research Boulevard, Suite 400, Rockville, MD 20850  |  Tel.: 301.984.9496  |  Fax: 301.770.1949